Houston, Texas–(Newsfile Corp. – November 11, 2020) – Psilocybin may just change the way we address mental health forever.
It may even revolutionize how major pharmaceutical giants tackle a good deal of mental health issues. After all, a recent study of 24 adults with major depression published in the journal JAMA Psychiatry found that two doses led to a large reduction in depression symptoms.
According to Alan Davis from the Johns Hopkins University School of Medicine, as quoted by New Atlas, “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market.”
“Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled clinical trials,” he added.
The U.S. is seeing broader support of psilocybin use, as well.
Just last week, Oregon became the first state to legalize psilocybin in a therapeutic setting. With Measure 109, the psilocybin movement is about overcoming depression, as noted by KATU 2 ABC. In addition, “An estimated 1 in every 5 adults in Oregon is coping with a mental health condition,” 20 doctors and other health care workers wrote in the voters’ pamphlet.
“We support Measure 109 because it provides a new treatment for many that might break through where others fall short.”
With big progress being made, psilocybin could change mental health treatment for the better.
Better Plant Sciences (CSE: PLNT) (OTC: VEGGF) is Part of the Growing Psilocybin Story
Better Plant Sciences’ majority owned subsidiary NeonMind Biosciences entered into a definitive agreement with Psygen Labs Inc. for the supply of psilocybin for NeonMind’s planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety.
“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, lead scientific advisor to NeonMind. “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings.”
“Psygen’s mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research,” says Danny Motyka, CEO of Psygen Labs Inc. “We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem.”
“Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics.”
For more information, visit the company’s website at https://betterplantsciences.com
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67961